Sarepta Therapeutics Inc (SRPT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2015||Independent Chairwoman of the Board|
|55||2017||President, Chief Executive Officer, Director|
|53||2017||Executive Vice President, Chief Financial Officer and Chief Business Officer|
|61||2017||Senior Vice President, Chief Scientific Officer|
|46||2012||Senior Vice President, General Counsel, Corporate Secretary|
- UPDATE 2-Summit plunges 80 pct after muscle-wasting disorder drug fails
- UPDATE 3-Sarepta shares soar as Duchenne gene therapy shows promise
- Sarepta stock soars as early-stage gene therapy data shows promise
- BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy
- BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28